Investment
Features
FeesSafety
Academy
More
Pluang+

Alnylam cuts 2026 sales forecast, shares drop over 28%, investors face potential losses

Market News
16 Aug 2026
PRNewsWire
View Source
Bearish
pluang ai news

Alnylam Pharmaceuticals lowered its full-year 2026 sales guidance by about $200 million due to slower growth after initial demand in the ATTR-CM market. This announcement led to a sharp drop in its stock price by more than 28%, causing significant losses for investors. A law firm is investigating possible securities law violations and is offering legal help to affected investors. This development highlights risks in biotech launches and potential legal recourse for shareholders.

More News (ALNY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App